• Share
  • Email
  • Embed
  • Like
  • Private Content
Mira Medicine Final Presentation
 

Mira Medicine Final Presentation

on

  • 70,716 views

 

Statistics

Views

Total Views
70,716
Views on SlideShare
3,397
Embed Views
67,319

Actions

Likes
1
Downloads
28
Comments
0

52 Embeds 67,319

http://steveblank.com 59571
http://www.linkedin.com 3668
https://www.linkedin.com 1176
http://www.inc.com 861
http://feedly.com 627
http://www.feedspot.com 355
http://medcitynews.com 177
http://www.huffingtonpost.com 170
http://www.google.com 144
http://www.newsblur.com 101
http://digg.com 92
http://newsblur.com 77
http://translate.googleusercontent.com 73
http://news.google.com 48
http://m.huffpost.com 33
http://www.feedreader.com 20
http://preview.inc.com 16
http://steveblank.wordpress.com 15
https://www.google.com 15
http://reader.aol.com 9
http://feeds.feedburner.com 7
http://steveblank.com. 6
http://www.inoreader.com 6
http://www.hanrss.com 5
http://inoreader.com 5
http://webcache.googleusercontent.com 4
http://vator.tv 4
http://q.feedspot.com 3
http://feedreader.com 3
https://www.google.ru 3
https://www.google.com.mt 2
http://www.pulse.me 2
http://www.google.fr 2
http://www.google.pl 1
http://50.34.250.101 1
http://www.google.ca 1
https://www.google.com.br 1
http://ranksit.com 1
http://player.vimeo.com 1
https://www.google.co.kr 1
http://reader.aol.co.uk 1
http://feeder.co 1
http://pulse.me&_=1388854844314 HTTP 1
http://pulse.me&_=1388898329972 HTTP 1
http://yoleoreader.com 1
http://plus.url.google.com 1
http://reader.inthemail.org 1
http://127.0.0.1 1
https://reader.aol.com 1
http://131.253.14.98 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • [[ SLIDE 1 TITLE ]] We Are MIRA Medicine a Spin- off from UCSF Neuroloogy and a first genetration of precision medicine application in complex diseaseWe deliver aster more precise clinical decision at low cost !
  • [[ SLIDE 2 Presentation ]] I am Raphy Loren Business Lead I am PA Gourraud analytics leads I am Jason Crane Software Lead
  • [[ SLIDE 3 STARTING POINT ]] [Raphaelle] Starting the LLP we had a rich man’s Problem ! We had developed a workingprototype, and almost each time we would demo it, our audience would come up with new opportunities – from augmenting the physician-patient relationship to We couldn’t choose between the 2 problems we were proposing to solve: helping patients with MS and solve the flood of data from modern medicine to change practiceThe problemturned into a bit of schizophrenia: are we a product company OR are we a Service company ? Offering what we did for MS as a Service for other research centers?Or build a MS-centered product to respond to the needs of community neurologists?--- [PA] “ an Application “ [Jason] OR a data analytics platform for all the complex diseases --[Raphaelle] We adopted the Steve Blanks’ s Method – Go and ask people outsdie the Lab ! And answer where is value in the platform of in the data you analysed but also when is the value ?Now with the protot or later with more than the proto . Are we a service company or a product company? [May not have to choose] A platform and an app? How do we provide value now and later? [Tiered model]What is our disease focus? [Neurological? Auto-immune conditions?
  • Complex, life-long diseases are very difficult to assess, predict, and treat efficiently.Multitude of factors to assess diseaseDeluge of data on each factorLack of visibility in disease progression at individual level and trends at population levelLow-reproducibility of assessment (primary score is aggregate)Frustrating and costly trial and error (increasing number of DMTs)Knowledgegap between specialty centers and community providers
  • average lifetime cost of treatment $1.2M+ trends from other industries (patients and physicians benefit from visualizations in other fields : travel, finance, education, real estate)
  • [[ SLIDE 3 STARTING POINT ]] [Raphaelle] Starting the LLP we had a rich man’s Problem ! We had developed a workingprototype, and almost each time we would demo it, our audience would come up with new opportunities – from augmenting the physician-patient relationship to We couldn’t choose between the 2 problems we were proposing to solve: helping patients with MS and solve the flood of data from modern medicine to change practiceThe problemturned into a bit of schizophrenia: are we a product company OR are we a Service company ? Offering what we did for MS as a Service for other research centers?Or build a MS-centered product to respond to the needs of community neurologists?--- [PA] “ an Application “ [Jason] OR a data analytics platform for all the complex diseases --[Raphaelle] We adopted the Steve Blanks’ s Method – Go and ask people outsdie the Lab ! And answer where is value in the platform of in the data you analysed but also when is the value ?Now with the protot or later with more than the proto . Are we a service company or a product company? [May not have to choose] A platform and an app? How do we provide value now and later? [Tiered model]What is our disease focus? [Neurological? Auto-immune conditions?
  • [[SLIDE 6]] We wanted to develop this great know-how for everyone TOO MANY VALUE PROP for TOO MANY CUSTOMER SEGMENTS So what did we learn from our interviews ? Pharmas, Clinicians. Researchers etcetc
  • Prisoners of our own solution:this existing solution was constraining us in finding needsToo many directions! Our BMC is a mess! Let’s narrow down to who has the biggest pain points and can pay for our offering, whether it’s a product or a service
  • Let’s narrow down to who has the biggest pain points and can pay for our offering, whether it’s a product or a servicewe refined the Value Proposition and Started chopping out the Customer Segments We excluded the MS patients, not because there is not demand but because we did not want to become a 23 and me for MS patients, too many regulatory problems.
  • Identify the best match between the Value Propositions and the multiple customer segments in order to find the easiest customer relations and channelsFeeling better Categorize interest and started to clarify it
  • We need validation!
  • PresentMIRA Spin off from UCSF NeurologyFirst product MIRA MS is the extension of the research tool MS BioscreenMarket: research centers, medical centers, and ACOs for MSVision for the future. Product vision MS: Augment the MS DB by 20x in 2 years Develop analytics for comparison and prediction Other diseases: Port model to Parkinson’s, RA, Alzheimer’s, Cognitive system platform for complex diseases by 2018
  • [[SLIDE 5 Our MARKET ]] [Raphaelle] With this Prototype we have a pretty clear MARKET POSITIONNING. “ Our offering places MIRA at the convergence of precision medicine, bioinformatics (knowledge management tools), and clinical care markets – each poised for exponential growth. The healthcare decision support market represented $202 million in 2012 and rapidly growing, thanks to mutually reinforcing factors, including: the dramatic reductions in costs of human genome sequencing; innovation and dramatic cost reductions in cloud-based data storage and parallel computing; new regulations such as the HIGHTECH Act of 2009, specifically the Meaningful Use incentives and requirements, are powerful drivers for adoption and use of Electronic Medical Records systems; consumer expectations of access to information and demand for quality of care; new reimbursement models based on quality of care and outcome, including Accountable Care Organizations. The nascent Clinical Care market is focused on providing tools that can be used by physicians at the point of care to amplify their expertise by complex, data-driven analyses, and is estimated at $100M in 2015. MIRA’s initial focus is on Multiple Sclerosis which has an incidence of 500,000 patients in the United States and 20,000 new cases identified every year. A life-long disease, Multiple Sclerosis has no cure, and currently approved Disease Modifying Therapies (DMTs) cost between $20-60,000 per patient per year. The MS therapeutics market, where 9 currently approved and 5 additional DMTs seeking FDA clearance are competing, is worth $7B per year in the US alone.If MIRA were to focus exclusively on MS, we would estimate our market size to 15-25M. By expanding to additional complex diseases and offering a platform, we estimate our market size at $100-200M.
  • …- It is already happening We are coached by a VC We have a research parternwho just got 900,000 awarded …
  • [[ SLIDE 1 TITLE ]] We Are MIRA Medicine a Spin- off from UCSF Neuroloogy and a first genetration of precision medicine application in complex diseaseWe deliver aster more precise clinical decision at low cost !
  • Value prop for physicians/cliniciansData-driven, personalized view supports patient education and communication (data-driven and visual) and shared decision makingVisual cues leads to better information retentionBetter retention and shared decision making lead to better adherence and hence efficacy and outcome.
  • Value prop for physicians/cliniciansData-driven, personalized view supports patient education and communication (data-driven and visual) and shared decision makingVisual cues leads to better information retentionBetter retention and shared decision making lead to better adherence and hence efficacy and outcome.

Mira Medicine Final Presentation Mira Medicine Final Presentation Presentation Transcript